Investment Thesis
IMMUNIC exhibits severe financial distress with negative stockholders' equity of -$6.7M, indicating technical insolvency. The company is burning $85.8M annually in operating cash while generating only $22K in revenue, leaving approximately 2 months of cash runway at current burn rates. Immediate capital raise or dramatic revenue inflection is required for survival.
Strengths
- Maintains $15.5M in cash providing near-term liquidity buffer
- Gross margin of 40.9% indicates viable unit economics if revenue scales
- Biotech sector exposure offers potential for transformative value if pipeline succeeds
Risks
- Negative stockholders' equity of -$6.7M represents technical insolvency
- Unsustainable cash burn: $85.8M operating cash flow deficit with $15.5M cash = ~2 month runway
- Minimal revenue generation ($22K) against $103.2M operating losses indicates pre-revenue stage dependency
- Current ratio of 0.75x signals immediate liquidity stress and inability to meet short-term obligations
- No long-term debt structure suggests capital markets access may be severely constrained
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Quarterly revenue growth and path to positive unit economics
- Occurrence and terms of any capital raises or financing events
- Operating cash flow trend and timing of operating cash flow inflection
Financial Metrics
Revenue
22.0K
Net Income
-97.2M
EPS (Diluted)
$-0.62
Free Cash Flow
-86.0M
Total Assets
24.1M
Cash
15.5M
Profitability Ratios
Gross Margin
40.9%
Operating Margin
-469,218.2%
Net Margin
-441,690.9%
ROE
N/A
ROA
-404.0%
FCF Margin
-390,759.1%
Balance Sheet & Liquidity
Current Ratio
0.75x
Quick Ratio
0.75x
Debt/Equity
N/A
Debt/Assets
127.7%
Interest Coverage
-7.22x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T19:18:22.603262 |
Data as of: 2025-12-31 |
Powered by Claude AI